United States Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and Forecasts, 2026-2034

Last Updated: September 01, 2026 | Author: Debashree Bora | Format:

United States Cardiac Resynchronization Therapy (crt) Market Size

The United States Cardiac Resynchronization Therapy Market size was valued at USD 1.28 billion in 2025 and is projected to grow from USD 1.40 billion in 2026 to reach USD 2.78 billion by 2034, growing at a CAGR of 8.99% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

Market Key Takeaways

Global Market Size & Growth

CRT-D dominates the market by Product.

Hospitals dominate the market by End-User.

United States Cardiac Resynchronization Therapy (CRT) Market Size

Download a Free Sample To learn more about this report.

Product Insights

The Middle East and Africa market is segmented by CRT-D and CRT-P. CRT-D dominated the market over the forecast period.

United States Cardiac Resynchronization Therapy (CRT) Market Size By Segments

Request Customizationto receive a tailored report.

End User Insights

The Middle East and Africa market is segmented by Hospitals, Cardiac Centre. Hospitals dominated the market over the forecast period.

United States Cardiac Resynchronization Therapy (CRT) Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

The U.S. cardiac resynchronization therapy market is anticipated to develop faster than average because of the rising death rate from cardiac illnesses. For instance, as of September 2021, the CDC estimates that 1 in every four fatalities in the U.S. was caused by heart disease. In addition, one of the main killers in the nation is heart disease. As a result, the market is projected to rise due to the large increase in demand for CRT to reduce mortality from cardiac diseases. Due to supportive government programs to enhance cardiovascular health, the U.S. CRT market is predicted to have significant growth. For instance, the National Health and Nutrition Examination Survey gathers information from the U.S. population to evaluate the prevalence of CVDs and their risk factors, including cigarette use, poor food choices, inactivity, and biometric measurements (DNA repositories & biospecimen). The information can assist the government in allocating private and public resources for CVD prevention and treatment. The country's CRT market is anticipated to increase due to these measures.

List of Key and Emerging Players in United States Cardiac Resynchronization Therapy (CRT) Market

Abbott

Boston Scientific Corporation

Medtronic

Biotronik SE & Co. Kg

Microport Scientific Corporation

LivaNova PLC

Medico S.R.L.

Key Industry Developments

June 2026

Abbott expanded its U.S. cardiac rhythm management portfolio with next-generation AI-enabled remote monitoring capabilities for implantable devices, enhancing patient management and clinical decision-making for heart failure and CRT patients.

May 2026

Medtronic received U.S. FDA approval for expanded MRI labeling of its Aurora EV-ICD™ MRI SureScan™ system, strengthening its advanced cardiac rhythm management portfolio for patients requiring implantable defibrillation and cardiac resynchronization therapy.

October 2025

Boston Scientific launched the AVVIGO+™ Multi-Modality Guidance System in the United States, expanding its electrophysiology portfolio with advanced intravascular imaging and physiology guidance to support complex cardiac procedures, including CRT lead implantation.

May 2025

BIOTRONIK received U.S. FDA approval for its Prospera™ Cardiac Resynchronization Therapy Pacemaker (CRT-P), expanding its cardiac rhythm management portfolio with advanced pacing technology designed for patients with heart failure requiring cardiac resynchronization therapy.

Report Scope

Segmentation

By Product 2

CRT-Defibrillator
CRT-Pacemaker

By End User 4

Hospitals
Cardiac Centers
Ambulatory Surgical Centers
Other End Users

Competitive Coverage Abbott · Boston Scientific Corporation · Medtronic · Biotronik SE & Co. Kg · Microport Scientific Corporation

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The United States cardiac resynchronization therapy market size was valued at USD 1.28 billion in 2025 and is projected to grow from USD 1.40 billion in 2026 to reach USD 2.78 billion by 2034, growing at a CAGR of 8.99% during the forecast period 2026–2034.

Key verticals adopting the United States cardiac resynchronization therapy market include: Abbott, Boston Scientific Corporation, Medtronic, Biotronik SE & Co. Kg, Microport Scientific Corporation, LivaNova PLC, Medico S.R.L.

Increasing prevalence of cardiovascular diseases is the key driver for the growth of the United States cardiac resynchronization therapy market.

The surge in elderly population is one of the upcoming key trends in the United States cardiac resynchronization therapy market.

About the Author

Debashree Bora

Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.